Coherus Oncology to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Coherus Oncology (NASDAQ: CHRS) said senior management will present at two investor conferences in March 2026 with webcasts and replays available on the company investor events calendar.

Presentations: TD Cowen Healthcare Conference on March 4, 2026 at 11:50 AM ET and Citizens Life Sciences Conference on March 10, 2026 at 2:50 PM ET. Replays will be posted for approximately 90 days.

REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus Oncology website: https://investors.coherus.com/events-presentations. A replay of the presentation will be available on this same website for approximately 90 days.

• 46^th Annual TD Cowen Healthcare Conference in Boston, on Wednesday, March 4, 2026, at 11:50 a.m. Eastern Daylight Time
• Citizens Life Sciences Conference in Miami, on Tuesday, March 10, 2026, at 2:50 p.m. Eastern Daylight Time

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

LOQTORZI® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.

Coherus Oncology Contact Information:

For Investors:

Carrie Graham
Vice President, Investor Relations & Advocacy
IR@coherus.com

FAQ

When will Coherus Oncology (CHRS) present at the TD Cowen Healthcare Conference in 2026?

Coherus Oncology will present on March 4, 2026 at 11:50 AM ET. According to the company, the presentation will be webcast and accessible via the investor events calendar, with a replay available on the same site for approximately 90 days.

How can I watch the Coherus Oncology (CHRS) presentation at the Citizens Life Sciences Conference on March 10, 2026?

The presentation will be available via webcast posted on the company investor events calendar. According to the company, a replay will also be provided on that page and remain available for about 90 days after the event.

Where is the Coherus Oncology (CHRS) webcast link for the March 2026 investor presentations?

The webcast link is on the Investor Events Calendar at investors.coherus.com/events-presentations. According to the company, both live webcasts and replays for roughly 90 days will be posted there for investor access.

Will Coherus Oncology (CHRS) make a replay of its March 2026 conference presentations available?

Yes, replays will be posted and available for approximately 90 days. According to the company, replay access will be on the investor events calendar page after each conference presentation.

What times are Coherus Oncology (CHRS) presenting at investor conferences in March 2026?

Coherus Oncology is scheduled for March 4, 2026 at 11:50 AM ET and March 10, 2026 at 2:50 PM ET. According to the company, both sessions will be webcast and viewable via the investor events calendar.